# AVANZAR (NCT05687266)

> Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05687266
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: NSCLC
- Interventions: Datopotamab deruxtecan; Durvalumab; Carboplatin; Pembrolizumab; Cisplatin; Pemetrexed; Paclitaxel
- Enrollment: 1350
- Primary outcome: Progression-Free Survival (PFS) by blinded independent central review (BICR) in the non-squamous TROP2 biomarker positive population
- Primary outcome: Overall Survival (OS) in the non-squamous TROP2 biomarker positive population
- Primary outcome: PFS by BICR in the non-squamous population
- Primary outcome: OS in the non-squamous population

## Commentary we found

- Podcasts: 12
- YouTube: 11
- X threads: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=avanzar-nct05687266

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05687266", "email": "<work email>"}; the inbox owner confirms by the emailed link.